UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302

Molecular cancer therapeutics, 2012-03, Vol.11 (3), p.740-751

2012

Link zum Volltext

Verfügbarkeit prüfen

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models

Translational oncology, 2018-08, Vol.11 (4), p.911-919

2018

Link zum Volltext

Verfügbarkeit prüfen

Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition

BMC cancer, 2015-05, Vol.15 (1), p.422-422, Article 422

2015

Link zum Volltext

Verfügbarkeit prüfen

705 Anti-tumor activity of CB-668, a potent, selective and orally bioavailable small-molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1)

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A423-A424

2020

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the Luting Cement Space for Provisional Restoration by using Various Coats of Die Spacer Materials-An Invitro Study

Journal of clinical and diagnostic research, 2014-09, Vol.8 (9), p.ZC22-ZC25

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3867: DNA repair processes involved with the hypoxia-activated prodrug TH-302: comparison to cisplatin and temozolomide

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3867-3867

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3289: Mechanistic studies of the potentiation of hypoxia-targeted drug TH-302 by co-administration of checkpoint kinase1 (Chk1) inhibitors

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3289-3289

2013

Link zum Volltext

Verfügbarkeit prüfen

Discovery of a Series of Potent, Selective, and Orally Bioavailable Nucleoside Inhibitors of CD73 That Demonstrates In Vivo Antitumor Activity

Journal of medicinal chemistry, 2023-01, Vol.66 (1), p.345-370

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2803: Distinct roles of intracellular ROS in cisplatin and evofosfamide cytotoxicity

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2803-2803

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer

Cancer biology & therapy, 2015-03, Vol.16 (3), p.438-449

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 6093: IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets homologous-recombination-deficient and PARP inhibitor resistant breast and ovarian tumors

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.6093-6093

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4134: Reversal of adenosine-mediated immune suppression by CB-708, an orally bioavailable and potent small molecule inhibitor of CD73

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4134-4134

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1784: Enhancement of hypoxia-activated prodrug TH-302 activity by Chk1 inhibition

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.1784-1784

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5497: An efficient clonogenic assay for cytotoxic drug screening

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.5497-5497

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2648: Pharmacological modulation of TH-302-mediated in vitro cytotoxicity

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.2648-2648

2011

Link zum Volltext

Verfügbarkeit prüfen

14-Aminocamptothecins: Their Synthesis, Preclinical Activity, and Potential Use for Cancer Treatment

Journal of medicinal chemistry, 2011-03, Vol.54 (6), p.1715-1723

2011

Link zum Volltext

Verfügbarkeit prüfen

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models1

Translational oncology, 2018-05, Vol.11 (4), p.911-919

2018

Link zum Volltext

Verfügbarkeit prüfen

Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models

American journal of cancer research, 2015-01, Vol.5 (7), p.2139-2155

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract A42: Antiangiogenic-induced increase in tumor hypoxia in RCC and NSCLC human tumor xenografts and its selective targeting by the hypoxia-activated prodrug TH-302: A model for clinical exploration?

Clinical cancer research, 2010-07, Vol.16 (14_Supplement), p.A42-A42

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5054: Hypoxia-activated prodrug TH-302 enhances antitumor activity of antiangiogenics in preclinical models

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.5054-5054

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 535: Hypoxia-dependent in vivo activity of the hypoxia-activated prodrug (HAP) TH-302

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.535-535

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2263: NADPH-cytochrome P450 reductase reduction of TH-302, a hypoxia-activated prodrug

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.2263-2263

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract A22: Hypoxia-dependent antitumor activity of TH-302, a hypoxia-activated prodrug, in preclinical pancreatic xenograft models

Clinical cancer research, 2010-07, Vol.16 (14_Supplement), p.A22-A22

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract 762: 14-Aminocamptothecin: Synthesis, preclinical activity, and potential use for cancer treatment

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.762-762

2010

Link zum Volltext

Verfügbarkeit prüfen

Deletion mutational analysis of BMRP, a pro-apoptotic protein that binds to Bcl-2

Molecular and cellular biochemistry, 2011-05, Vol.351 (1-2), p.217-232

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(9)
Science & Technology
(9)
Animals
(6)
Oncology
(6)
Humans
(5)
Mice
(5)
Care And Treatment
(3)
Cell Line, Tumor
(3)
Hypoxia-Activated Prodrug
(3)
Antineoplastic Agents - Pharmacology
(2)
Apoptosis - Drug Effects
(2)
Cell Survival - Drug Effects
(2)
Chemistry, Medicinal
(2)
Comparative Analysis
(2)
Diagnosis
(2)
Dna Damage
(2)
Dna Damage - Drug Effects
(2)
Female
(2)
Health Aspects
(2)
Histones - Metabolism
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models

Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition

705 Anti-tumor activity of CB-668, a potent, selective and orally bioavailable small-molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1)

Evaluation of the Luting Cement Space for Provisional Restoration by using Various Coats of Die Spacer Materials-An Invitro Study

Abstract 3867: DNA repair processes involved with the hypoxia-activated prodrug TH-302: comparison to cisplatin and temozolomide

Abstract 3289: Mechanistic studies of the potentiation of hypoxia-targeted drug TH-302 by co-administration of checkpoint kinase1 (Chk1) inhibitors

Discovery of a Series of Potent, Selective, and Orally Bioavailable Nucleoside Inhibitors of CD73 That Demonstrates In Vivo Antitumor Activity

Abstract 2803: Distinct roles of intracellular ROS in cisplatin and evofosfamide cytotoxicity

Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer

Abstract 6093: IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets homologous-recombination-deficient and PARP inhibitor resistant breast and ovarian tumors

Abstract 4134: Reversal of adenosine-mediated immune suppression by CB-708, an orally bioavailable and potent small molecule inhibitor of CD73

Abstract 1784: Enhancement of hypoxia-activated prodrug TH-302 activity by Chk1 inhibition

Abstract 5497: An efficient clonogenic assay for cytotoxic drug screening

Abstract 2648: Pharmacological modulation of TH-302-mediated in vitro cytotoxicity

14-Aminocamptothecins: Their Synthesis, Preclinical Activity, and Potential Use for Cancer Treatment

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models1

Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models

Abstract A42: Antiangiogenic-induced increase in tumor hypoxia in RCC and NSCLC human tumor xenografts and its selective targeting by the hypoxia-activated prodrug TH-302: A model for clinical exploration?

Abstract 5054: Hypoxia-activated prodrug TH-302 enhances antitumor activity of antiangiogenics in preclinical models

Abstract 535: Hypoxia-dependent in vivo activity of the hypoxia-activated prodrug (HAP) TH-302

Abstract 2263: NADPH-cytochrome P450 reductase reduction of TH-302, a hypoxia-activated prodrug

Abstract A22: Hypoxia-dependent antitumor activity of TH-302, a hypoxia-activated prodrug, in preclinical pancreatic xenograft models

Abstract 762: 14-Aminocamptothecin: Synthesis, preclinical activity, and potential use for cancer treatment

Deletion mutational analysis of BMRP, a pro-apoptotic protein that binds to Bcl-2

Suchergebnisse filtern